Last reviewed · How we verify
Drug conversion to sirolimus
Sirolimus is an mTOR inhibitor that suppresses T-cell proliferation and immune activation to prevent organ rejection.
Sirolimus is an mTOR inhibitor that suppresses T-cell proliferation and immune activation to prevent organ rejection. Used for Prevention of organ rejection in renal transplant recipients, Conversion therapy in transplant patients to reduce calcineurin inhibitor exposure.
At a glance
| Generic name | Drug conversion to sirolimus |
|---|---|
| Also known as | Rapamune |
| Sponsor | Hospital do Rim e Hipertensão |
| Drug class | mTOR inhibitor |
| Target | mTOR (mammalian target of rapamycin) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Sirolimus (rapamycin) binds to FKBP12 and inhibits the mammalian target of rapamycin (mTOR), a key signaling protein in cell proliferation and survival. This mechanism reduces T-cell and B-cell activation, making it effective as an immunosuppressant in transplant recipients. Drug conversion protocols involve switching patients from other immunosuppressants (such as calcineurin inhibitors) to sirolimus-based regimens to optimize long-term graft outcomes and reduce nephrotoxicity.
Approved indications
- Prevention of organ rejection in renal transplant recipients
- Conversion therapy in transplant patients to reduce calcineurin inhibitor exposure
Common side effects
- Hyperlipidemia
- Thrombocytopenia
- Anemia
- Delayed wound healing
- Mouth ulcers
- Diarrhea
- Pneumonitis
Key clinical trials
- HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide (PHASE2)
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation (PHASE1, PHASE2)
- Liver Transplantation With Tregs at MGH (PHASE1, PHASE2)
- Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
- Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal (PHASE4)
- Precision Medicine Offers Belatacept Monotherapy (PHASE4)
- Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction (PHASE4)
- Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug conversion to sirolimus CI brief — competitive landscape report
- Drug conversion to sirolimus updates RSS · CI watch RSS
- Hospital do Rim e Hipertensão portfolio CI